{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:57:15Z","timestamp":1792065435290,"version":"4.4.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":271,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A 29-year-old woman presented with fever, malar rash, and alopecia. Laboratory evaluation demonstrated a high-titre antinuclear antibody of 1:5120, hypocomplementaemia, and positivity for anti\u2013double-stranded DNA and anti-Smith antibodies, leading to a diagnosis of systemic lupus erythematosus (SLE). During the clinical course, she developed progressive peripheral neuropathy with inability to walk. Intravenous methylprednisolone pulse therapy and intravenous immunoglobulin were administered, but neurological improvement was limited, and intravenous cyclophosphamide (IVCY) therapy was initiated. Subsequently, she developed central nervous system manifestations of neuropsychiatric SLE and received an additional course of intravenous methylprednisolone. Central nervous system manifestations gradually improved during ongoing IVCY therapy; however, fever, rash, and alopecia persisted at the time of transfer to our hospital. Because fever persisted despite antibiotic therapy and mucocutaneous manifestations and hypocomplementaemia progressively worsened, residual SLE activity was considered clinically relevant. Anifrolumab (ANF) was initiated on hospital Day 28, coinciding with completion of antibiotic therapy. Fever resolved the following day, while the mucocutaneous manifestations and hypocomplementaemia subsequently showed gradual and sustained improvement. No serious infectious or other adverse events were observed after ANF initiation during ongoing IVCY therapy. Reports describing add-on ANF during ongoing IVCY therapy for severe SLE are extremely limited. This case highlights the potential role of ANF as an adjunctive therapy for persistent systemic and mucocutaneous manifestations suggestive of interferon-associated disease activity during ongoing cyclophosphamide-based intensive immunosuppressive treatment.<\/jats:p>","DOI":"10.1093\/mrcr\/rxag092","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:39:58Z","timestamp":1790681998000},"source":"Crossref","is-referenced-by-count":0,"title":["Add-on anifrolumab for residual mucocutaneous and systemic manifestations during cyclophosphamide therapy in severe neuropsychiatric lupus: a case report"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7930-4828","authenticated-orcid":false,"given":"Mariko","family":"Hoshino","sequence":"first","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Hospital , Sakai, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3110-4976","authenticated-orcid":false,"given":"Toshihiko","family":"Shiga","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Hospital , Sakai, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Hospital , Sakai, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Hospital , Sakai, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nozaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Hospital , Sakai, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Hospital , Sakai, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University Hospital , Sakai, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2026101507362500100_ref1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.molmed.2020.09.009","article-title":"Leveraging heterogeneity in systemic lupus erythematosus for new therapies","volume":"27","author":"Allen","year":"2021","journal-title":"Trends Mol Med"},{"key":"2026101507362500100_ref2","doi-asserted-by":"publisher","first-page":"i55","DOI":"10.1093\/rheumatology\/kew427","article-title":"Pathways leading to an immunological disease: systemic lupus erythematosus","volume":"56","author":"Zharkova","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026101507362500100_ref3","doi-asserted-by":"publisher","first-page":"e000270","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2026101507362500100_ref4","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-\u03b1 pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026101507362500100_ref5","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2026101507362500100_ref6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026101507362500100_ref7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/acr.25690","article-title":"American College of Rheumatology guideline for the treatment of systemic lupus erythematosus","volume":"78","author":"Sammaritano","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026101507362500100_ref8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2026101507362500100_ref9","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2026101507362500100_ref10","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus, TULIP-1: a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2026101507362500100_ref11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2026101507362500100_ref12","doi-asserted-by":"publisher","first-page":"rxaf065","DOI":"10.1093\/mrcr\/rxaf065","article-title":"Anifrolumab as a glucocorticoid-sparing agent in MRI-negative myelitis associated with neuropsychiatric lupus: a case report","volume":"9","author":"Suda","year":"2025","journal-title":"Mod Rheumatol Case Rep"},{"key":"2026101507362500100_ref13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/03009742.2024.2306053","article-title":"Refractory systemic lupus erythematosus with neuropsychiatric manifestations successfully treated with anifrolumab","volume":"53","author":"Kobayashi","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"2026101507362500100_ref14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41584-018-0156-8","article-title":"Neuropsychiatric lupus: new mechanistic insights and future treatment directions","volume":"15","author":"Schwartz","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2026101507362500100_ref15","doi-asserted-by":"publisher","first-page":"102631","DOI":"10.1016\/j.coi.2025.102631","article-title":"Neuropsychiatric lupus: a myriad of symptoms requires a myriad of models","volume":"96","author":"Sullivan","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"2026101507362500100_ref16","doi-asserted-by":"publisher","first-page":"1078607","DOI":"10.3389\/fpsyt.2023.1078607","article-title":"Mouse models, antibodies, and neuroimaging: current knowledge and future perspectives in neuropsychiatric systemic lupus erythematosus","volume":"14","author":"Tomalla","year":"2023","journal-title":"Front Psychiatry"},{"key":"2026101507362500100_ref17","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1097\/MD.0000000000000625","article-title":"Peripheral neuropathies due to systemic lupus erythematosus in China","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2026101507362500100_ref18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2026101507362500100_ref19","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and type I interferon responses in cutaneous lupus are driven by epidermal-derived interferon-kappa","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026101507362500100_ref20","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/jcm8081244","article-title":"Molecular profiling of cutaneous lupus lesions identifies subgroups distinct from clinical phenotypes","volume":"8","author":"Berthier","year":"2019","journal-title":"J Clin Med"},{"key":"2026101507362500100_ref21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/mrcr\/rxae018","article-title":"Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus","volume":"8","author":"Azuma","year":"2024","journal-title":"Mod Rheumatol Case Rep"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxag092\/71465040\/rxag092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/2\/rxag092\/71465040\/rxag092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/2\/rxag092\/71465040\/rxag092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:36:33Z","timestamp":1792064193000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxag092\/8845407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxag092","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rxag092"}}